1,566 results on '"Melero, Ignacio"'
Search Results
52. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
53. 617 A Phase I study of a tumor-targeted, fibroblast activation protein (FAP)-CD40 agonist (RO7300490) in patients with advanced solid tumors
54. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
55. Intratumoral co‐injection of NK cells and NKG2A‐neutralizing monoclonal antibodies
56. Druggable Targets in Cytokine Release Syndromes
57. Contributors
58. Designing clinical studies for biomarker discovery: The Design criteria
59. Rapid isolation and enrichment of mouse NK cells for experimental purposes
60. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
61. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
62. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
63. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
64. Cytokines in clinical cancer immunotherapy
65. Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011
66. Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
67. Defining the Critical Hurdles in Cancer Immunotherapy
68. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
69. Facts and Hopes on Neutralization of Protumor Inflammatory Mediators in Cancer Immunotherapy
70. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies
71. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
72. Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium
73. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming.
74. Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies
75. International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain
76. A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
77. Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
78. Supplementary Figures from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
79. Supplementary Data from Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
80. Supplementary Figure from A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β
81. Abstract 1100: 4-1BBL agonist targeted to fibroblast activation protein α synergizes with radiotherapy in murine breast tumor
82. Data from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
83. Data from Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer
84. Data from Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
85. Data from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
86. Abstract 614: CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects
87. Supplementary Figure from Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
88. Supplementary Tables from CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function
89. Data from A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β
90. Supplementary Data from Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer
91. Supplementary Figure from Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer
92. Data from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
93. Data from Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
94. Supplementary Table 3 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
95. Supplementary Table 1 from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
96. Supplementary Data from A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
97. Supplementary Figure 2 from Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
98. Supplementary Figure 2 from Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
99. Supplementary figure 3 from TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
100. Data from CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.